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Abstract
Lung cancer has become the most commonly diagnosed cancer and the leading cause of
cancer deaths globally. The major problem of the high mortality rate is the late diagnosis.
Conventional methods utilized for clinical detection of lung cancer have employed expensive
and invasive medical procedures that cause stress, discomfort, and pain to patients, and have
demonstrated low sensitivity, substantial false negatives, and risk of radiation exposure. The
drawbacks obviate their applicability to large-scale, population-wide screening efforts. This
paper reviews the applications of using volatile organic compounds (VOCs) in exhaled breath as
a potential approach for early lung cancer detection.
An electronic search was conducted in PubMed and Scopus. A total of 41 studies were
included in this review. The sampling method of exhaled breath employed in most of the
included studies were leak-proof Tedlar bags. Mass spectrometry and electronic noses were two
main techniques used in breath sample detection. In the recent years, electronic noses gained
more popularity due to their portability and cost-effectiveness. In this review, a total of 40
VOCs, originated from both endogenous and exogenous sources, were found to be significant in
discriminating between lung cancer patients and healthy controls in two or more of the included
studies. The included studies demonstrated substantial sensitivity, specificity, and accuracy of
the method. Overall, the results showed that VOCs in exhaled breath is a promising biomarker
for early detection of lung cancer. However, the large-scale practice of this method is constrained
by the lack of standardized breath collection and analysis system and putative exhaled VOC
biomarkers. Further studies with consistent sampling protocols should be used to demonstrate the
reproducibility and repeatability of the detection tool before they are applied in clinical practice.
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Introduction
Lung cancer has become the most commonly diagnosed cancer as well as the leading
cause of cancer deaths globally, with 2.1 million people diagnosed in 2018 and 1.8 million
deaths. Increases in environmental risk factors are expected to contribute to enhanced number of
1

new lung cancer cases. According to the International Agency for Research on Cancer, the
number of incident cases is estimated to be 2.9 million in 2030, which is 38.1% higher than the
incident cases in 2018.

2

There are two major types of lung cancer: non-small cell lung cancer (NSCLC) and small
cell lung cancer (SCLC). Non-small cell lung cancer accounts for 85% of all lung cancer cases
and can be classified into three histologic types: squamous cell carcinoma, adenocarcinoma, and
large cell carcinoma. Regardless of the histopathological subtype, the five-year mortality rate of
3

the lung cancer patients is 88%, suggesting that late diagnosis as a problem. Early diagnosis of
4-6

lung cancer associates with far better survival than diagnosis at a later stage. The five-year
survival rate after detection varies between 45% of patients with stage I and 1% of patients with
stage IV. However, the five-year survival rate increases to 60%-80% if diagnosed at early stage.
5

4

Unfortunately, only 15% of the lung cancer patients are diagnosed at stage I, and more than half
lung cancer patients die in the first year of being diagnosed.

7

Traditionally, combinations of techniques, such as radiological imaging (i.e., computed
radiography and computed tomography [CT]), non-radiological imaging (i.e., magnetic
resonance imaging and automatic fluorescence bronchoscopy), endoscopic (i.e., endocytoscopy)
and molecular biotechnology, are used to detect lung cancer. All these methods are useful at
6

various stages of lung cancer diagnosis but are not sufficiently satisfactory for early detection.
Nearly a quarter of lung cancer patients showed no suspected malignant changes when evaluated
with chest X-ray, indicating a low sensitivity. On the other hand, Zhou et al. reported that if
8

purely based on the morphological criteria, it is difficult to distinguish lung cancer from benign
nodules, which could lead to increased false positives, and resulting unnecessary surgical
resection procedures. Although low dose chest CT screening test was reported to reduce the lung
6

cancer mortality by 20%, the low positive predictive value (PPV) of CT (2.4% to 5.2%) has
9

raised concerns of substantial false positives.

10-12

In addition, chest CT is expensive and there are

risks associated with radiation exposure. The potential drawbacks of the existing techniques
9

1

obviate their applicability to large-scale screening efforts. Therefore, there is an urgent need for
alternative tools for early lung cancer detection.
Breath analysis as a screening method for lung cancer has obtained attention in the last
decades and it is a fast-growing research field. Human exhaled breath contains a mixture of
hundreds of volatile organic compounds (VOCs). These VOCs either enter the body from
13

polluted air, food intake, and radiation exposure or produced endogenously by the body itself. In
14

a healthy individual, the amount of VOCs produced by human metabolism is very low, ranging
from parts per million to parts per trillion by volume. However, in some diseased conditions (i.e.,
lung cancer), the metabolic functions in body are altered and VOC concentrations are
significantly changed. Therefore, VOCs may reflect the biochemical status and changes of the
15

body and provide insight to diseases.
An initial study by Gordon et al. in 1985 demonstrated the potential of measuring VOCs
16

in human breath as a potential for lung cancer screening. The increased prevalence of lung
cancer has resulted in a recent increase in development of new techniques and methodologies for
VOC measurement in exhaled breath. As of now, a Tedlar bag is often used to collect exhaled
breath. Mass spectrometry and electronic nose (e-nose) are commonly used tools to detect and
17

analyze VOCs in the exhaled breath. The mass spectrometry technique is able to identify the
specific individual VOCs contained in the breath, whereas an e-nose resembles the function of
human olfactory organs do with odorants and recognize patterns of VOCs. The response of e18

nose when exposed to exhaled breath is usually referred as the smell-print.
A relatively large number of articles has been published on the topic, however, results of
the studies have been inconsistent. This up-to-date review is intended to list and rank the
previously identified VOCs for lung cancer screening among the studies, discuss the potential
biochemical pathways of altered VOC concentrations in lung cancer patients, compare and
contrast the spectrometric and e-nose detection methods, and offer suggestions for future
research. This review may be helpful for the development of a lung cancer screening approach.

2

Methods
An electronic search extending back to 1980 was conducted using PubMed and Scopus
on December 2018 based on the guidelines of PRISMA. The main terms used to search for titles
19

and abstracts were (exhaled OR breath OR exhalation) and (VOCs OR volatile organic
compounds) and (lung cancer OR lung carcinoma). Table 1 provides a detailed search strategy
for each database used. Cross-referencing from the articles found was used to complete the
search. Inclusion in the systematic review required that a study be 1) original research with
VOCs detected in human subjects; 2) with at least two groups (i.e., lung cancer patients and
disease-free controls); 3) lung cancer proved by pathology; and 4) published in English. Studies
were excluded if they met one of the following criteria: 1) no controls were matched to the lung
cancer patients; 2) not an original research paper (i.e., case report, review, and systematic
review/meta-analysis); 3) full text is not written in English; 4) study of lung cancer treatment
progress or prognosis; and 5) collection and analysis of bronchoscopic air samples.
For each study, the author, sample collection/extraction/ detection methods, statistical
analysis method, number of targeted biomarkers, and sensitivity/ specificity/accuracy were
extracted, if applicable. In this review, the overall sensitivity, specificity and accuracy data from
the models consisted of a group of VOCs were reported. In some studies, compound-specific
sensitivity, specificity and accuracy for discriminating between the lung cancer patients and
controls were reported if the group-specific sensitivity and specificity were not available.
Sensitivity is the probability that a test correctly classifies those with disease, whereas specificity
is the probability that a test correctly classifies those without disease. Accuracy is the proportion
of all subjects who test correctly. They can be calculated as:

544,+14( =

!"#$%&%'%&( =

&+," -.$%&%'"
&+," -.$%&%'" + 012$" #"31&%'"

!-"4%0%4%&( =

&+," #"31&%'"
&+," #"31&%'" + 012$" -.$%&%'"

&+," -.$%&%'" + &+," #"31&%'"
&+," -.$%&%'" + 012$" -.$&%&%'" + &+," #"31&%'" + 012$" #"31&%'"

Single VOC found to be significant in discriminating between lung cancer patients and
healthy controls in two or more of the included studies are also reported.
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Results
A total of 641 papers were found by using the search strategy discussed above. After
removing for duplicates, 480 were remained for abstract and full text screening. During the
screening process, 430 studies were excluded for not meeting the inclusion criteria, leaving a
total of 50 studies for full-text review. During the full-text screening, an additional 9 studies
were excluded, leaving a total of 41 studies

16, 20-59

for analysis, as shown in Figure 1. Table 2 lists

authors and titles of the studies included in this review.
The included studies represent exhaled breath sample analysis from 10 countries around
the world, where almost half (18/41) were conducted in the United States or China (nine studies
from even country, respectively). The sampling method of exhaled breath employed in most of
the included studies were gas sampling bags (i.e., Tedlar bags). Tedlar bags are leak-proof
polymer bags with different sizes (in volumes). However, the sampling protocols varied across
the included studies. Among the 41 studies, 21 collected the alveolar portion of the breath, 19
collected all portions of exhaled breath, and 1 study did not report the breath collection portion.
Several studies used a fast response CO controlled manner to collect alveolar air samples.
2

Different subject preparation practices before breath sample collection were used among
the included studies. A few studies required the participants to fast overnight for 12 or 24
hours.20,25,43,46,58 A couple more asked their participants to eat nothing 2 hours before the breath
test.30 Several studies required each subject to follow the same diet and the same procedure for
mouth hygiene before sample collection.21,46,56 Three studies asked their participants to refrain
from eating foods with strong odors, such as garlic, leeks, and onions or any spicy food 24 hours
before breath sample collection.47,52,58 Although all of the included studies involved smokers,
only three studies required their participants to stop smoking for 10 or 12 hours before the
sample collection.43,47,54 Another study asked the study subjects to stop smoking and chewing
gum prior to the breath sample collection.58
In order to distinguish between endogenous and exogenous compounds, room/ambient air
samples were collected as reference in many of the included studies. At the stage of sample
analysis, a common approach applied was to take the difference between exhaled breath and
room air to control for the confounding effect of background air. Another two used an approach
where only VOCs with concentrations at least 10% or 15% higher in exhaled breath than those in
the ambient air were reported.

33,40

One study only included VOCs with amount more than the

4

ambient level. A few other studies considered a correlation coefficient > 0.50 between the
38

exhaled breath and background air as potential background air pollution.
Two main techniques were used to detect VOCs from exhaled breath: mass spectrometry
(n=25) and e-noses (n=16). Among the spectrometric methods, gas chromatography coupled
with mass spectrometry (GD/MS) was the most commonly used method to detect VOCs in
exhaled breath samples (n=17). Table 3 summarizes the characteristics of the papers with an
spectrometry detection technique. Among the 16 studies used e-noses, the sampling system were
quite different. Six studies used non-selective quartz microbalance (QMC) sensors, 3 studies
used a handheld portable Cryanose 320, another 3 studies used metal oxide sensors, 2 studies
used a colorimetric sensor array, and one study used a surface acoustic wave (SAW) sensor
connected to gas chromatography. Table 4 summarizes the characteristics of the papers with an
e-noses detection method and Table 5 provides a brief summary of the different types of sensors.
Lung-cancer specific VOCs can be classified into seven categories: alkanes/alkenes,
alcohols, aldehydes, ketones, esters, nitriles, and aromatic compounds. More than 100 VOCs
60

were found in the exhaled breath of lung cancer patients in the included papers. Figure 2
summarizes the 40 VOCs detected in two or more studies. Among all studies, isoprene and
propanol were the most commonly detected VOC from exhaled breath found to be significantly
different between lung cancer patients and healthy subject controls, which was detected in 12/41
studies respectively. Other frequently detected VOCs included benzene, hexanal, acetone, and
decane. Among all studies, increased VOC concentrations were observed in lung cancer patients
as compared to healthy controls, with only a few exceptions.
Most of the studies reported the sensitivity and specificity data constructed by a group of
VOCs. The sensitivity ranged from 54% to 100%, and the specificity ranged from 58.6% to
100%. For mass spectrometry detection methods specifically, the sensitivity ranged from 54% to
100%, and the specificity ranged from 58.6% to 100%. For the e-nose detection method, the
sensitivity ranged from 70% to 100%, and the specificity ranged from 72.4% to 100%. However,
as aforementioned, not all mass spectrometry and sensor systems were the same. The accuracy
reported from the included studies ranged from 79.6%-100%.
Most of the studies included in this systematic review did not compare the VOCs in
exhaled breath from lung cancer patients across different disease stages. Among the studies that
reported the differences, three studies did not find significant differences in VOCs from exhaled
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breath in patients at different disease stages.

29,34,46

However, Fu et al. reported significantly lower 2-

butanone in exhaled breath of stage I patients, compared to patients with stages II-IV NSCLC.
Measured 2-butanone concentrations did not differ among stages II-IV patients. Ma et al. found
44

significantly higher concentrations of exhaled methanol, acetone, propanol, and pentane in
patients with stage IV than stage IIIb lung cancer. However, the concentration of isoprene in
exhaled breath did not differ between stage IV and stage IIIb lung cancer patients. Using an e47

nose, Gasparri et al. reported a sensitivity of 92% to lung cancer patients with stage I as
compared to a sensitivity of 58% to pung cancer patients with stages II-IV. In a more recent
52

study, Oguma et al. found significantly increased cyclohexane and xylene concentrations as the
clinical stage of lung cancer advanced.

55

Similar to the lung cancer stages, only several studies compared the differences in
VOCs in exhaled breath of lung cancer patients with different histological types. Song et al.
detected a significantly higher concentration of 1-butanol and 3-hydroxy-2-butanone in exhaled
breath from lung cancer patients with adenocarcinoma compared to those with squamous cell
carcinoma. Wang et al. observed significant concentration differences on 5 VOCs (834

hexylpentadecane; 3,7-dimethylpentadecane; 8-methylheptadecane; 2-pentadecanone; 5propylnonane) between the squamous cell carcinoma group and adenocarcinoma group. While
43

Fuchs et al. did not observe significant differences in exhaled pentanal, octanal, and nonanal
concentrations between patients with small cell lung cancer (SCLC) and non-small cell lung
cancer (NSCLC), patients with SCLC exhaled significantly more hexanal than NSCLC patients.

36

Fu et al. detected a significantly elevated concentration of 4-hydroxyhexenal in exhaled breath
from lung cancer patients with squamous cell carcinoma than that from adenocarcinoma group.

44

Oguma et al. did not find statistically significant differences in cyclohexane and xylene
concentrations among lung cancer patients with different histological types.

55

Among the studies that examined the potential confounding effects from age, gender, or
smoking, almost all found that VOCs profile was independent from these factors, except for a
few exceptions. Bajtarevic et al. found that isoprene presented age- and gender- specific
behavior. Ulanowska et al. found significantly increased concentrations of acetonitrile, benzene,
33

and furan derivatives from healthy passive and active smokers.

39
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Discussions
A critical aspect of breath analysis is the collection of the breath samples. Depending on
the sampling time, portion, and analysis of the study, the profile of VOCs can be greatly
different. The included studies collected either the total exhaled breath or the alveolar air (at the
end of the exhaled breath). In human breath, one third of breath are dead-space air from mouth,
nose, pharynx, trachea, and bronchi, and two-thirds of breath are from the lung alveolar.

61

Previous studies showed that concentrations of VOCs at the end of the exhaled breath can be a
couple times higher than those from entire exhaled breath, and the removal of the dead-space air
62

showed enhanced identification of lung cancer by e-nose. In addition, due to the fact that the
63

exogenous sources of VOCs may alter the VOC concentrations found in the exhaled breath, a
standardized protocol on subject preparations before the breath sample collection and an
agreement on the breath portion are crucial. Among all, fasting and smoking are believed to be
the two major issues associated with exogenous sources of VOCs. Due to the large variability on
the subject preparations among the included studies, it was difficult to compare the study results
to one another.
Two main techniques were used to detect VOCs in exhaled breath: mass spectrometry
and e-noses. The spectrometric techniques are sensitive and accurate. The main advantage of
using GC/MS is the ability to identify specific VOC compounds and obtain their concentrations
in the exhaled breath samples. However, the spectrometric techniques have several drawbacks
that limit their application in a clinical setting for large population screening. First, the
spectrometry techniques are comparatively expensive. Second, the technique usually requires
pre-concentration (i.e., solid phase microextraction [SPME]) before analysis, so it does not offer
quick and real-time analysis of the breath samples. SPME extraction may be influenced by many
conditions, including the type of fiber film, extraction time, temperature, and humidity.

64

Depending on the sampling protocol, the accuracy of the analysis could be very different. Third,
due to the complexity of the operation, trained individuals are required to perform the analysis.
Fourth, the GC/MS devices are usually not portable. Last, the GC/MS requires constant
calibration of the analytes.

65

In the recent years, it seems like the researchers are moving to a more portable and costeffectiveness method called e-noses. Unlike spectrometry analysis, the goal of e-nose
measurement is to detect the patterns of VOCs. E-noses are arrays of non-selective sensors that

7

resembles the function of human olfactory organs do with odorants. Non-selective means that
each sensor is sensitive to a wide range of VOCs, but the sensitivity for each individual
compound of the sensor array is different. Therefore, it is possible to detect the overall patterns
of the VOCs. The detection of VOCs by e-nose are based on the changes in physical signals,
21

such as electrical resistance, oscillation frequency, and color. Compared to the mass
spectrometry technique, e-nose are portable, cheaper, and able to achieve real-time (or near realtime) analysis, which is more feasible in clinical settings. While the pattern recognition of enoses demonstrated its accuracy in diagnostic assessment in the included studies, spectrometric
techniques are essential in determining the specific individual VOC to understand their
pathophysiological pathways and to identify a group of VOCs that are critical in discriminating
between lung cancer patients and controls. Therefore, at least for now, more studies should be
done in both GC/MS and e-nose techniques to find the specific VOCs and shape the optimal
sensors for future use in clinical practice.
As aforementioned, a total of 40 VOCs in exhaled breath were found to be significantly
different between lung cancer patients and controls in two or more of the included studies. VOCs
in exhaled breath could be originated from both endogenous and exogenous sources. At current
stage, it is still not clear on how the VOCs are linked to the biochemical pathways of lung cancer
cells. It is hypothesized that lung cancer patients have predisposed, high-risk groups of
cytochrome p450 enzymes in their body. When exposed to environmental toxins, such as
tobacco smoke, the enzymes are induced, which potentially modulate the catabolism of the
VOCs in the body, ultimately leading to detectable changes in VOCs from exhaled breath.

66

Hakim et al. have extensively reviewed the evidence of volatile organic compounds of lung
60

cancer and possible biochemical pathways. Here, we briefly summarize the potential pathways in
the context of the relevant VOCs identified from the included papers.
Alkanes/Alkenes. The main mechanism which affects the production of unbranched
alkanes/alkenes in the body is oxidative stress. These compounds are produced from lipid
peroxidation of polyunsaturated fatty acids by reactive oxygen species. Polyunsaturated fatty
acids are found mainly in cellular and subcellular membranes in the body. Since these fatty acids
contain multiple double bonds with methylene -CH - groups, they tend to be peroxidated.

60
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Among the branched hydrocarbons, isoprene was the most commonly found VOC. Isoprene is
believed to be produced non-enzymatically through the mevalonic acid pathway of cholesterol

8

synthesis in the liver. While most of the studies found increased concentrations of isoprene in
67

lung cancer patients as compared to the controls, two studies reported the opposite findings. It
29,33

might be explained by the fact that isoprene concentration changes quickly during even minor
physical effort, such as leg or arm contractions. Therefore, the concentrations of isoprene in
exhaled breath could be quite different among studies if the sampling protocol were different.

60

Alcohols. Alcohols are mainly originated from food and alcohol beverages in the
gastrointestinal tract, and metabolism of alkanes by cytochrome p450 enzymes. These alcohols
can then be metabolized to aldehydes by enzymes in the liver. The unmetabolized alcohols are
excreted in breath, urine, etc. In the included studies, propanol concentration was found to be
higher in the exhaled breath of lung cancer patients than the controls. This could be explained by
the fact of hydroxylation of the lipid peroxidation biomarkers by cytochrome p450 enzymes.

60

Aldehydes. There are four major sources of aldehydes in the body. The first source relates
to the alcohol metabolism in the liver by group of enzymes, such as alcohol dehydrogenase and
cytochrome p450 (CYP2E1). The second source relates to the secondary product of lipid
60

peroxidation by cytochrome p450 enzymes. The third source relates to the cigarette smoke. The
last source relates to the byproducts of tobacco metabolism by cytochrome p450 during the
detoxication process. In the included studies, the concentrations of seven straight aldehydes
60

were found to be significantly higher in the exhaled breath of lung cancer patients, as compared
to the healthy controls. The elevated levels of aldehydes found in the exhaled breath of lung
cancer patients could be explained by the increase in aldehyde dehydrogenase activity in the lung
cancer cell per se or the aldehyde dehydrogenase-2 enzyme mutation.

60

Nitriles. Acetonitrile, a component of tobacco smoke, was the only nitrile found to be
significant in differentiating between lung cancer and healthy controls in exhaled breath.
Bajtarevic et al. observed higher acetonitrile concentrations in lung cancer smokers as compared
to lung cancer ex-smokers. In another study, acetonitrile was found to be in higher concentration
33

in lung cancer ex-smokers as compared to healthy smokers. Some other included studies also
37

found higher concentration of acetonitrile in smokers as compared to non-smokers. The
29

proposed pathways is that acetonitrile is biotransformed into cyanohydrine by cytochrome p450
monooxygenase, and then decomposes into hydrogen cyanide and formaldehyde. Since
acetonitrile metabolism is happening very slow in the body, a significant amount of acetonitrile
is excreted out the body through exhaled breath and/or urine.

60
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Ketones. Ketones are secondary products of lipid peroxidation. For example, acetone, a
good predictor of ketosis, is formed from the high oxidation rates of fatty acids in lung cancer
patients as well as with a weight loss. In addition, the formation of acetone and other ketone
bodies occurs mostly in the final stage of lung cancer, when cachexia occurs. Acetone is
60

exhaled through breath due to its high vapor pressure. Butanone and pentanone were found to be
in higher concentrations in the exhaled breath from lung cancer patients compared to the
controls. Instead of produced endogenously, butanone is believed to be absorbed to the body
through exogenous sources.
Aromatic compounds. Aromatic compounds are considered exogenous pollutants
originated from cigarette smoke, alcohol drinking, air pollution, and radiation exposure. These
compounds are highly reactive. They may leak into the cytoplasm, posing peroxidative damage
to proteins, polyunsaturated fatty acids, and DNA, and finally cause damage to biological
organelles, stimulating cancer. It is believed that the lung cancer patients have absorbed these
exogenous aromatic compounds in their fatty acids, which then slowly and constantly released
into the exhaled breath.

60

The sensitivity and specificity reported in the included studies ranged from 54% to 100%,
and 58.6% to 100%, respectively. For mass spectrometry detection methods specifically, the
sensitivity ranged from 54% to 100%, and the specificity ranged from 58.6% to 100%. For the enose detection method, the sensitivity ranged from 70% to 100%, and the specificity ranged from
72.4% to 100%. The accuracy among the reported studies ranged from 82% to 100%. Sensitivity,
specificity and accuracy are three important measures of the validity of the test results. A high
sensitivity corresponds to a high negative predicted value (proportion of those test negative do
not have the disease), which is significant in rule out the individuals. On the contrary, a high
specificity corresponds to a high positive predictive value (proportion of those test positive
actually have the disease), which is significant in rule in the patients. All the studies should aim
68

for the highest sensitivity and specificity if possible. If both cannot be achieved at the same time,
a high specificity is more desirable than a high sensitivity to avoid excess identification of false
positive results. False positive results may lead to monetary costs associated with further
diagnostic tests, psychological stress, discomfort from further diagnostic tests, and burden on
health care-system.

69
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As stressed in many studies, a single VOC was not enough to discriminate lung cancer
patients from healthy controls. A group of VOCs were needed to be included in the models to
achieve substantial sensitivity, specificity, and accuracy. Both endogenous and exogenous could
be interesting candidates for lung cancer biomarkers. More studies should be done to investigate
their production mechanisms and clinical value of screening lung cancer. In addition, the wide
range of VOCs detected in the current studies implies the lack of repeatability and
reproducibility of the studies. Due to the variation in sampling methods among these studies, a
standardized method for breath collection and analysis is highly desired in future studies in order
to achieve easier external comparison.
There are several limitations of the included studies. One limitation is that well-defined
groups of ‘pure’ healthy volunteers or patients with specific lung disease were included.
However, in real life practice, the patients are more heterogeneous, with additional VOCs due to
complications of lung cancer and other related diseases. Another limitation is the lack of
comparison of cancer stages and histologic types. Due to relatively small sample sizes, many of
the included studies were not able to analyze lung cancer subgroups. Concerns still exist on
whether exhaled breath analysis could detect lung cancer in early stage. At last, as several
included studies observed significant differences in some of the VOCs concentrations in lung
cancer patients with different stages or different histologic subtypes, further analyses are much
needed to verify the existing findings. Standardized multicenter studies with much larger and
diverse patient populations are necessary. There are also limitations of this systematic review.
Due to a small number of the included studies reported the information, this review did not
report the ranges of VOC concentrations detected from the lung cancer patients and healthy
controls of the included studies. In addition, this review did not take a full in-depth review on the
statistical analysis used in the studies. There was a large heterogeneity regarding the statistical
techniques used in the included studies. In future analysis, researches should review the existing
techniques, and reach a consensus on which data processing techniques should be used. Since the
objectives of this review were considered to be better answered and understood with qualitative
analysis, meta-analysis was not done in this review.
Nevertheless, even with all the limitations, the results suggested that VOCs in exhaled
breath is a promising tool for early detection of lung cancer in clinical practice. This approach
fulfills the World Health Organization principles of early disease detection. First, lung cancer is
70
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an important health problem. It is the most commonly diagnosed cancer and the leading cause of
cancer death globally. Second, the tumor formation process is relatively complex. The overall
latency for lung cancer from all types of exposure is rather long. The latency reported to be the
shortest was lung cancer associated with chromium exposures, which had a minimum of 4
years. Third, the exhaled breath analysis is a relatively practical, efficient and cost-effective
71

tool. Breath collection is a simple, rapid, and convenient process that requires minimum efforts
from the patients. In addition, the sampling process is non-invasive that may be acceptable and
safe to everyone in the population. Comparing to the existing tests and treatments, exhaled breath
collection and analysis is also the most cost-effective approach. Included studies had
demonstrated its high validity that do not identify a large number of false positives. Last, when
diagnosed with lung cancer, there are accepted treatments available, i.e., chemotherapy, surgery,
etc. However, further studies should be done is to demonstrate if early detection of lung cancer
from exhaled breath is truly effective in reducing mortality, as lead-time bias and length-time
bias are usual concerns in the assessments of survival time in screening studies.

72

Conclusions
Based on the results from this review, exhaled breath analysis in early lung cancer
detection is an interesting and promising strategy but still constrained by the lack of standardized
breath collection and analysis system and putative exhaled VOC biomarkers. Therefore,
considerations for further studies should include: 1) standardize the methods for breath collection
and analysis; 2) identify a group of VOCs in exhaled breath that is specific to lung cancer; 3)
compare VOC profiles in lung cancers patients with different stages and histology; and 4) test
the feasibility and reliability of the practice in larger and more diverse populations.
Funding
There is no funding to be reported.
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Appendix
Table 1. Summary of search strategy
Database
PubMed

Scopus

Search Strategy
Number of References
(exhaled[Title/Abstract] OR breath[Title/Abstract] OR
333
exhalation[Title/Abstract] OR smell-print[Title/Abstract]
OR exhalation[MeSH Terms] OR breath tests[MeSH
Terms]) AND (VOCs[Title/Abstract] OR volatile organic
compounds[Title/Abstract] OR volatile[Title/Abstract] OR
chromatography, gas[MeSH Terms] OR electronic
nose[MeSH Terms]) AND (lung[Title/Abstract] OR lung
cancer[Title/Abstract] OR lung carcinoma[Title/Abstract]
OR lung tumor[Title/Abstract] OR lung
malignancy[Title/Abstract] OR lung neoplasms[MeSH
Terms])
(TITLE-ABS308
KEY ( breath OR exhaled OR exhalation ) AND TITLEABS-KEY ( vocs OR "volatile organic
compounds" OR volatile ) AND TITLE-ABSKEY ( "lung cancer" OR "lung carcinoma" OR "lung
tumor" OR "lung malignancy" OR "lung neoplasm" )
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Figure 1: Detailed diagram on the selection of articles
Articles identified from PubMed (n=333)

Articles identified from Scopus (n=308)

Candidate articles identified after duplicates (n=480)

Articles excluded on titles and abstracts (n= 430)
• Irrelevant to the topic of interest
• Not original research
• No controls
• Animal studies
• Study of treatment response and prognosis
• Others

Candidate articles included for full-text review (n=50)

Articles excluded on full-text (n=9)
• Not written in English
• No controls
• Bronchoscopic air sample

Articles included in analysis (n=41)
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Table 2. List of papers included in the analysis
Author
Gordon et al.
Phillips et al.
Di Natale et al.
Phillips et al.
Machado et al.
Poli et al.
Yu et al.
Chen et al.
Phillips et al.
Mazzone et al.
Wehinger et al.
Chen et al.
Dragonieri et al.
Westhoff et al.
Bajtarevic et al.
Song et al.
D’Amico et al.
Fuchs et al.
Kischkel et al.
Rudnicka et al.
Ulanowska et al.
Buszewski et al.
Mazzone et al.
Santonico et al.
Wang et al.
Fu et al.
Handa et al.
Zou et al.

Title
Volatile organic compounds in exhaled air from patients with lung cancer
Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study
Lung cancer identification by the analysis of breath by means of an array of non-selective gas sensors
Detection of lung cancer with volatile markers in the breath
Detection of lung cancer by sensor array analyses of exhaled breath
Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested shortterm follow-up study
Solid phase microextraction for analysis of alkanes and aromatic hydrocarbons in human breath
A non-invasive detection of lung cancer combined virtual gas sensors array with imaging recognition technique
Prediction of lung cancer using volatile biomarkers in breath
Diagnosis of lung cancer by the analysis of exhaled breath with a colorimetric sensor array
Lung cancer detection by proton transfer reaction mass-spectrometric analysis of human breath gas
A study of the volatile organic compounds exhaled by lung cancer cells in vitro for breath diagnosis
An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD
Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung
cancer: Results of a pilot study
Noninvasive detection of lung cancer by analysis of exhaled breath
Quantitative breath analysis of volatile organic compounds of lung cancer patients
An investigation on electronic nose diagnosis of lung cancer
Breath gas aldehydes as biomarkers of lung cancer
Breath biomarkers for lung cancer detection and assessment of smoking related effects - confounding variables,
influence of normalization and statistical algorithms
Determination of volatile organic compounds as biomarkers of lung cancer by SPME–GC–TOF/MS and
chemometrics
The application of statistical methods using VOCs to identify patients with lung cancer
Identification of volatile lung cancer markers by gas chromatography-mass spectrometry: comparison with
discrimination by canines
Exhaled breath analysis with a colorimetric sensor array for the identification and characterization of lung cancer
In situ detection of lung cancer volatile fingerprints using bronchoscopic air-sampling
The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines
Noninvasive detection of lung cancer using exhaled breath
Exhaled breath analysis for lung cancer detection using ion mobility spectrometry
Optimization of volatile markers of lung cancer to exclude interferences of non-malignant disease

Ref.
16
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
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Ma et al.

Determination of breath gas composition of lung cancer patients using gas chromatography/mass spectrometry
with monolithic material sorptive extraction
Rudnicka et al.
Determination of volatile organic compounds as potential markers of lung cancer by gas chromatography-mass
spectrometry versus trained dogs
Phillips et al.
Blinded Validation of Breath Biomarkers of Lung Cancer, a Potential Ancillary to Chest CT Screening
Rocco et al.
BIONOTE e-nose technology may reduce false positives in lung cancer screening programmes
Schallschmidt et Comparison of volatile organic compounds from lung cancer patients and healthy controls—challenges and
al.
limitations of an observational study
Gasparri et al.
Volatile signature for the early diagnosis of lung cancer
Shehada et al.
Silicon Nanowire Sensors Enable Diagnosis of Patients via Exhaled Breath
Sakumura et al.
Diagnosis by Volatile Organic Compounds in Exhaled Breath from Lung Cancer Patients Using Support Vector
Machine Algorithm
Oguma et al.
Clinical contributions of exhaled volatile organic compounds in the diagnosis of lung cancer
Li et al.
Lung Cancer Screening Based on Type-different Sensor Arrays
Tirzīte et al.
Detection of lung cancer in exhaled breath with an electronic nose using support vector machine analysis
Cai et al.
A Prediction Model with a Combination of Variables for Diagnosis of Lung Cancer
van de Goor et al. Training and Validating a Portable Electronic Nose for Lung Cancer Screening

47
48
49
50
51
52
53
54
55
56
57
58
59
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Table 3. Characteristics of the papers included in the review with spectrometry detection method
Author

Year

Country

Study
Sample

Gordon et al.

1985

USA

Phillips et al.

1999

USA

Phillips et al.

2003

USA

Poli et al.

2005

Italy

Yu et al.

2005

China

Phillips et al.

2007

USA

Wehinger et
al.

2007

Austria

Chen et al.

2007

China

N=29;
12 NSCLC
patients;
17 healthy
controls
N=108;
60 LC
patients;
48 controls
N=108;
67 primary
LC
patients;
41 controls
N=146;
36 NSCLC
patients;
25 COPD;
85 controls
N=30;
15 LC
patients;
15 healthy
controls
N=404;
193 LC
patients;
211
controls
N=187;
17 LC
patients;
170
controls
N=49;
29 LC
patients;
7 chronic
bronchitis;

Collection
/Extraction
Method
Tenax GC
cartridge

Breath
Sample

Breath
Volume

Detection
Method

Statistical
Analysis
Method
Discriminant
function

Targeted
biomarkers

Sensitivity/
Specificity

Accuracy

Ref.

All

20 L

GC/MS

22 VOCs

100%/100%

93.0%

16

Portable
electrical
device +
sorbent trap
Portable
breath
collection
apparatus +
sorbent trap
Teflon®bulb +
SPME

End

10 L

GC/MS

Forward
stepwise DA
+ LOO

22 VOCs

For stage I:
100%/81.3%

N/A

20

End

1L

GC/MS

Forward
stepwise DA
+ LOO

9 VOCs

89.6%/82.9%

N/A

22

End

150 mL

GC/MS

Multinomial
logistic
regression

13 VOCs

72.2%/93.6%

82.5%

24

Tedlar bag
+ SPME

All

N/A

GC/MS

N/A

5 VOCs

N/A

N/A

25

Portable
breath
collection
apparatus +
sorbent trap
Tedlar bag

End

1L

GC/MS

Fuzzy logic
model +
MLR

16 VOCs

84.6%/80.0%

88.0%

27

All

3L

PTR/MS

Wilcoxon
rank sum
test

5 VOCs

Formaldehyde
+ propanol:
54.0%/99.0%

96.0%

29

Tedlar bag
+ SPME

All

5L

GC/FID

PCA

11 VOCs

86.2%/70.0%

79.6%

30

22

Westhoff et
al.

2009

Germany

Bajtarevic et
al.

2009

Austria

Song et al.

2010

China

Fuchs et al.

2010

Germany

Kischkel et al.

2010

Germany

Rudnicka et
al.

2011

Poland

Ulanowska et
al.

2011

Poland

13 healthy
controls
N=90;
36 LC
patients;
54 healthy
controls
N=96;
65 LC
patients;
31 healthy
controls
N= 84;
43 NSCLC
patients;
41 healthy
controls

Teflon®bulb +
sample loop

End

10 mL

IMS

LDA + LOO

23 VOCs

100%/100%

100%

32

Tedlar bag
+ SPME

All

3L

GC/MS

KruskalWallis test

21 VOCs

80%/100%

N/A

33

Tedlar bag
+ SPME

All

4L

GC/MS

Wilcoxon
rank sum
test

2 VOCs

1-butanol:
95.3%/85.4%;
3-hydroxy-2butanone:
93.0%/92.7%

N/A

34

N=36;
12 LC
patients;
12 healthy
smokers;
12 healthy
controls

Headspace
vial +
SPME

End

10 mL

GC/MS

KruskalWallis test

4 VOCs

N/A

36

N=93;
31 LC
patients;
31 healthy
smokers;
31 healthy
controls
N=53;
23 LC
patients;
30 healthy
controls
N=280;
137 LC
patients;
143 healthy
controls

Headspace
vial +
SPME

End

10 mL

GC/MS

PCA +
MannWhitney
rank test

42 VOCs

pentanal:
75.0%/95.8%;
hexanal:
8.3%/91.7%;
octanal:
58.3%/91.7%;
nonanal:
33.3%/95.8%
N/A

N/A

37

Tedlar bag
+ SPME

All

10 mL

GCTOF/MS

MannWhitney
rank test

55 VOCs

N/A

N/A

38

Tedlar bag
+ SPME

End

500 mL

GC/MS

DA +
CHAID

33 VOCs

N/A

N/A

39
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Buszewski et
al.

2012

Poland

Wang et al.

2012

China

Handa et al.

2014

Japan

Zou et al.

2014

China

Ma et al.

2014

China

Rudnicka et
al.

2014

Poland

Phillips et al.

2015

USA

N=73;
29 LC
patients;
44 healthy
controls
N=243;
88 LC
patients;
70 lung
benign
disease;
85 healthy
controls
N=89;
50 LC
patients;
39 healthy
controls
N=171;
79 LC
patients;
54 PNMD;
38 healthy
controls
N=38;
13 LC
patients;
25 healthy
controls
N=253;
108 LC
patients;
121 healthy
controls;
24 COPD
N=516;
175 LC
patients;
54 healthy
controls;
287 high
risk cancerfree
controls

Tedlar bag
+ SPME

End

200 mL

GC/MS +
PTR/MS

KruskalWallis test

19 VOCs

N/A

N/A

40

Tedlar bag
+ SPME

End

1L

GC/MS

LDA + LOO

23 VOCs

96.5%/97.5%

N/A

43

CO controlled
sample inlet
unit

End

10 mL

IMS

Decision
tree
algorithm

10 VOCs

76.0%/100.0%

N/A

45

Tedlar bag
+ SPME

End

N/A

GC/MS

ROC curves

15 VOCs

N/A

N/A

46

Tedlar bag
+ SPME

End

3L

GC/GCFID

PLS-DA +
MannWhitney test

5 VOCs

N/A

N/A

47

Tedlar bag
+ SPME

End

1L

GC/MS

ANN +
CHAID

88 VOCs

74.0%/73.0%

N/A

48

Portable
electrical
device +
sorbent trap

End

1L

GC/MS

Multivariate
weighted
digital
analysis

N/A

Unblinded:
74.0%/70.7%
Blinded:
1.
68.0%/68.4%
2.
71.0%/68.0%

N/A

49

2

24

Schallschmidt
et al.

2016

Germany

Sakumura et
al.

2017

Japan

Oguma et al.

2017

Japan

N=60;
37 LC
patients;
23 healthy
controls
N=136;
107 LC
patients;
29 healthy
controls
N=153;
116 LC
patients;
37 healthy
controls

Gas bulb +
SPME

All

1L

GC/MS

LDA + LOO

24 VOCs

84.0%/78.0%

81.7%

51

Analytic
Barrier Bag
+ cold trap

End

1L

GC/MS

SVM +
LOO

5 VOCs

91.6%/58.6%

89.0%

54

Sampling
bag + cold
trap

All

N/A

GC-FID

MannWhitney test

14 VOCs

Cyclohexane:
53.0%/78.0%;
Xylene:
49.0%/86.0%;
Cyclohexane
and xylene
combined:
75.0%/78.0%

N/A

55

ANN: artificial neural networks; CHAID: chi-squared automatic interaction detector; COPD: chronic obstructive pulmonary disease;
DA: discriminant analysis; GC-FID: gas chromatography coupled with flame ionization detector; GC/GC-FID: flow-modulated
comprehensive two-dimensional gas chromatography and flame ionization detector; GC/MS: gas chromatography coupled with mass
spectrometry; GC-TOF/MS: gas chromatography-time of flight-mass spectrometry; IMS: ion mobility spectrometry; LC: lung cancer;
LD: lung disease; LDA: linear discriminate analysis; LOO: leave-one-out cross validation; MLR: multilinear regression analysis; N/A:
not available; NSCLC: non-small cell lung cancer; PCA: principal component analysis; PNMD: pulmonary non-malignant diseases;
PTR/MS: proton transfer reaction mass spectrometry; ROC: receiver operating curve; SPME: solid-phase microextraction; SVM:
support vector machine
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Table 4. Characteristics of the papers included in the review with e-nose detection method
Author

Year

Country

Study
Sample

Di Natale et
al.

2003

Italy

Machado et
al.

2005

USA

Chen et al.

2005

China

Mazzone et
al.

2007

USA

Dragonieri et
al.

2009

Netherlands

D’Amico et
al.

2010

Italy

N=60;
35 LC
patients;
18 controls;
9 LC
patients
(postsurgery)
N=135;
28 LC
patients;
57 other
LD;
50 controls
N=50;
24 LC
patients;
8 chronic
bronchitis;
18 healthy
controls
N=143;
49 NSCLC;
73 other
LD;
21 healthy
controls
N=30;
10 NSCLC;
10 COPD;
10 healthy
controls
N=92;
28 LC
patients;
36 healthy
controls;
28 other
LDs

Collection
/Extraction
Method
Disposable
bag

Breath
Sample

Breath
Volume

Detection
Method

Statistical
Analysis
Method
PLS-DA +
LOO

Targeted
biomarkers

Sensitivity/
Specificity

Accuracy

Ref.

All

1.3 L

e-nose

Profile

100%/94%

90.3%

21

Nonreactive
Mylar gassampling
bag

All

N/A

e-nose

SVM

Profile

71.4%/91.9%

85%

23

Tedlar bag
+ SPME

All

N/A

e-nose

ANN

11 VOCs

N/A

N/A

26

N/A

All

N/A

e-nose

Random
forest

Profile

73.3%/72.4%

N/A

28

Tedlar bag

All

N/A

e-nose

PCA +
linear CDA

Profile

N/A

N/A

31

Tedlar bag

End

3L

e-nose

PLS-DA +
LOO

Profile

85%/100%

N/A

35

26

Mazzone et
al.

2012

USA

N=229;
92 LC
patients;
137
controls

Disposable
corrugated
tubing

All

N/A

e-nose

Logistic
prediction
models

Profile

81.1%;
89.0%

41

Profile

NSCLC vs.
controls:
70.0%/86.0%;
SCLC vs.
controls:
89.0%/85.0%
85.0%/85.0%

Santonico et
al.

2012

Italy

Tedlar bag

End

3L

e-nose

PLS-DA +
LOO

Fu et al.

2014

USA

Tedlar bag

All

1L

e-nose

Rocco et al.

2015

Italy

Pneumopipe
+ Adsorbing
cartridge

All

N/A

Gasparri et al.

2016

Italy

Tedlar bag

End

Shehada et al.

2016

Israel

N/A

Li et al.

2017

China

N=30;
20 NSCLC;
10 controls
N=217;
97 LC
patients;
88 healthy
controls;
32 benign
pulmonary
nodules
N=100;
23 LC
patients;
12 COPD;
65 Controls
N=146;
70 LC
patients;
76 healthy
controls
N=374;
149 LC
patients;
56 AC
patients;
40 GC
patients;
129
controls
N=52;
24 LC
patients;
5 other LD;
23 healthy
controls

85.0%

42

Wilcoxon
rank sum
test

4 VOCs

89.8%/81.3%

87.6%

44

e-nose

PLS-DA +
LOO

Profile

86.0%/95.0%

N/A

50

3L

e-nose

PLS-DA +
LOO

Profile

81.0%/91.0%

N/A

52

N/A

N/A

e-nose

ANN +
discriminant
function

Profile

87.0%/82.0%

84.0%

53

Tedlar bag

All

2L

e-nose

LDA-Fuzzy
5-NN +
SVM

Profile

91.6%/91.7%

91.6%

56

27

Tirzīte et al.

2017

Latvia

Cai et al.

2017

China

van de Goor
et al.

2018

Netherlands

N=335;
165 LC
patients;
91 other
LD;
79 healthy
controls
N=129;
57 LC
patients;
72 healthy
controls
N=167;
60 LC
patients;
107 healthy
controls

Tedlar bag

All

N/A

e-nose

SVM

N/A

98.8%/81.0%

93.0%

57

Devex bag

End

1L

e-nose

MannWhitney test

23 VOCs

76.0%/94.0%

82.8%

58

N/A

End

N/A

e-nose

ANN

Profile

Training set:
83.0%/84.0%
Validation set:
88.0%/86.0%

Training
set:
83.0%;
Validation
set: 86.0%

59

AC: asthma and COPD; ANN: artificial neural networks; CDA: canonical discriminant analysis; COPD: chronic obstructive
pulmonary disease; e-nose: electronic nose; GC: gastric cancer; LC: lung cancer; LD: lung disease; LDA: linear discriminate analysis;
LOO: leave-one-out cross validation; N/A: not available; NSCLC: non-small cell lung cancer; PLS-DA: partial least square
discriminant analysis; SVM: support vector machine
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Table 5: Summary of different types of e-noses used in the included studies.
Sensor type
QMB sensors

Cyranose 320

•
•
•
•
•

SAW sensors

•
•

Colorimetric

•
•

Metal oxide sensors

•
•
•
•

Description
Non-selective quartz microbalance (QMB) gas sensors, coated with different metalloporphyrins.
The VOCs adsorb to the coatings, therefore changing the mass of the quartz crystal and its
oscillation frequency.
A type of conductive polymer gas sensor
A handheld portable chemical vapor analyzer, containing a nanocomposite array of 32 carbonblack polymer sensors.
When exposed to VOCs, the sensors swell, thereby changing the electrical resistance, resulting in
a unique smellprint of differential electrical resistances.
A pair of surface acoustic wave (SAW) gas sensors coated with poly-isobutylene (PIB) film.
When exposed to VOCs, the layer coated on the surface adsorb specific VOCs, leading to mass
and velocity changes on the surface, which could be monitored by counting the frequency of the
sensor.
A colorimetric sensor array contains 36 chemically sensitive spots impregnated on a disposable
cartridge.
Each spot has different sensitivities to VOCs. The colors of these spots change based on the
chemicals with which they come into contact.
Types: silicon microreactors and Aeonose.
Silicon microreactors are composed of a ceramic support tube coated with silicon oxide
micropillars.
Aeonose consists of three micro hotplate metal oxide sensors with different surface properties.
Redox reactions of the VOCs at the surfaces of the metal oxide sensors induce conductivity
change of the sensors.

Reference
[21], [35], [42],
[50], [52], [58]
[23], [31], [57]

[26]

[28], [41]

[36], [53], [59]
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Figure 2: Summary of volatile organic compounds groups detected in two or more studies
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